SM
Sabby Management Portfolio holdings
AUM
$13M
This Quarter Return
-0.19%
1 Year Return
-26.95%
3 Year Return
-56.43%
5 Year Return
-61.92%
10 Year Return
-71.17%
AUM
$339M
AUM Growth
+$339M
(+59%)
Cap. Flow
+$135M
Cap. Flow
% of AUM
39.85%
Top 10 Holdings %
Top 10 Hldgs %
57.87%
Holding
181
New
46
Increased
26
Reduced
25
Closed
28
Top Buys
| 1 |
Weyerhaeuser
WY
|
$64.6M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$34M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$8.75M |
| 4 |
AGN
Allergan plc
AGN
|
$7.45M |
| 5 |
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
|
$5.83M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$11M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
$8.78M |
| 3 |
Sarepta Therapeutics
SRPT
|
$6.71M |
| 4 |
SPDR S&P Biotech ETF
XBI
|
$6.23M |
| 5 |
Thermo Fisher Scientific
TMO
|
$4.65M |
Sector Composition
| 1 | Healthcare | 64.94% |
| 2 | Real Estate | 19.41% |
| 3 | Energy | 2.49% |
| 4 | Consumer Discretionary | 1.61% |
| 5 | Communication Services | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ECYT
176
DELISTED
Endocyte, Inc. Common Stock
ECYT
| – | – |
0
| – | – |
|
|
KERX
177
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| – | – |
-167,999
| Closed | -$2.86M |
|
178
iShares Russell 2000 ETF
IWM
$66.3B
| – | – |
0
| – | – |
|
|
CELG
179
DELISTED
Celgene Corp
CELG
| – | – |
-19,499
| Closed | -$2.72M |
|
|
AUXL
180
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| – | – |
0
| – | – |
|